Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Increase in Short Interest

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 32,118 shares, a growth of 112.6% from the January 15th total of 15,105 shares. Based on an average daily trading volume, of 31,647 shares, the short-interest ratio is currently 1.0 days. Currently, 0.3% of the company’s shares are sold short. Currently, 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 31,647 shares, the short-interest ratio is currently 1.0 days.

Radiopharm Theranostics Stock Down 2.0%

RADX stock opened at $4.90 on Friday. The business has a 50-day moving average of $5.15 and a 200-day moving average of $5.39. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $16.25.

Institutional Trading of Radiopharm Theranostics

A number of institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in Radiopharm Theranostics in the fourth quarter valued at $76,000. Marex Group plc acquired a new position in shares of Radiopharm Theranostics during the 4th quarter worth about $54,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Radiopharm Theranostics by 100.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock valued at $88,000 after acquiring an additional 8,000 shares in the last quarter.

Analyst Ratings Changes

RADX has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Thursday, January 22nd. Wall Street Zen lowered Radiopharm Theranostics to a “strong sell” rating in a research report on Friday, January 23rd. Finally, B. Riley Financial reiterated a “buy” rating and issued a $16.00 price objective (up from $13.00) on shares of Radiopharm Theranostics in a research report on Tuesday, December 16th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Radiopharm Theranostics presently has a consensus rating of “Buy” and a consensus price target of $15.33.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.